• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Lenz Robert A.

    3/10/26 4:16:37 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBRX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Lenz Robert A.

    (Last) (First) (Middle)
    C/O LB PHARMACEUTICALS INC
    ONE PENNSYLVANIA PLAZA, SUITE 1025

    (Street)
    NEW YORK NY 10119

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/06/2026
    3. Issuer Name and Ticker or Trading Symbol
    LB PHARMACEUTICALS INC [ LBRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Marc Panoff, Attorney-in-Fact 03/10/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LBRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBRX

    DatePrice TargetRatingAnalyst
    1/9/2026Buy
    Roth Capital
    10/6/2025$27.00Buy
    Stifel
    10/6/2025$78.00Overweight
    Piper Sandler
    10/6/2025$34.00Outperform
    Leerink Partners
    More analyst ratings

    $LBRX
    SEC Filings

    View All

    LB Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)

    3/10/26 8:15:13 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals Inc

    SCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)

    2/17/26 4:35:14 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)

    2/5/26 8:15:20 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Deep Track Biotechnology Master Fund, Ltd. converted options into 686,138 shares and bought $39,999,990 worth of shares (2,666,666 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 6:09:13 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussbaum Ran converted options into 411,681 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:05 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Pontifax Management 4 G.P. (2015) Ltd. bought $15,000,000 worth of shares (1,000,000 units at $15.00) and converted options into 411,681 shares (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:07 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

    3/9/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals to Participate in Upcoming March Investor Events

    NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that management will present and participate in the following upcoming investor conferences: Leerink 2026 Global Healthcare Conference Date: Wednesday, March 11, 2026Time: 1:40 p.m. ET Stifel 2026 Virtual CNS ForumDate: Tuesday, March 17, 2026Time: 2:30 p.m. ET A live webcast of the presentations will be available on the "Investors" section under the "Events" s

    3/4/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

    2/27/26 11:44:00 AM ET
    $ATAI
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $LBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on LB Pharmaceuticals

    Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy

    1/9/26 9:05:22 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on LB Pharmaceuticals with a new price target

    Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    10/6/25 8:30:35 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on LB Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of LB Pharmaceuticals with a rating of Overweight and set a new price target of $78.00

    10/6/25 8:30:14 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lenz Robert A.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:19:34 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lenz Robert A.

    3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:16:37 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    2/10/26 4:30:04 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Leadership Updates

    Live Leadership Updates

    View All

    LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

    3/9/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg

    1/21/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea

    1/6/26 7:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care